title: Multikinase inhibitors in thyroid cancer.
authors.affiliation: Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. lisa.licitra@istitutotumori.mi.it
authors.forename: Lisa
authors.initials: L
authors.lastname: Licitra
authors.forename: Laura D
authors.initials: LD
authors.lastname: Locati
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000188:drug therapy / Q000473:pathology; D018276:Carcinoma, Medullary / Q000151:congenital* / Q000188:drug therapy / Q000473:pathology; D018278:Carcinoma, Neuroendocrine; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007456:Iodine Isotopes / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D018813:Multiple Endocrine Neoplasia Type 2a / Q000188:drug therapy / Q000473:pathology; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D007456:Iodine Isotopes; D047428:Protein Kinase Inhibitors; D003606:Dacarbazine; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf